Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial

被引：0
作者：
Jürgen Behr
Petra Neuser
Antje Prasse
Michael Kreuter
Klaus Rabe
Carmen Schade-Brittinger
Jasmin Wagner
Andreas Günther
机构：
[1] University of Munich (LMU) and Asklepios Fachkliniken München-Gauting,Department of Internal Medicine V, Comprehensive Pneumology Center
[2] Philipps University of Marburg,Coordinating Center for Clinical Trials
[3] Hannover Medical School,Department of Respiratory Medicine
[4] University of Heidelberg,Department of Pneumology and Respiratory Critical Care Medicine, Thoraxklinik
[5] Lungenclinic Grosshansdorf and University of Kiel,Department of Internal Medicine II
[6] University of Giessen-Marburg Lung Center,undefined
[7] Justus-Liebig University Giessen,undefined
[8] AGAPLESION Lung Clinic Waldhof-Elgershausen,undefined
来源：
BMC Pulmonary Medicine | / 17卷
关键词：
Oral Pirfenidone; Conventional Anti-inflammatory Therapy; Chronic Hypersensitivity Pneumonitis; Interstitial Lung Disease (ILD); Idiopathic Pulmonary Fibrosis (IPF);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 155 条
[91]  
Liu G(undefined)undefined undefined undefined undefined-undefined
[92]  
Cheresh P(undefined)undefined undefined undefined undefined-undefined
[93]  
Kim SJ(undefined)undefined undefined undefined undefined-undefined
[94]  
Mueller A(undefined)undefined undefined undefined undefined-undefined
[95]  
Lam AP(undefined)undefined undefined undefined undefined-undefined
[96]  
Trejo H(undefined)undefined undefined undefined undefined-undefined
[97]  
Williams D(undefined)undefined undefined undefined undefined-undefined
[98]  
Tulasiram S(undefined)undefined undefined undefined undefined-undefined
[99]  
Baker M(undefined)undefined undefined undefined undefined-undefined
[100]  
Ridge K(undefined)undefined undefined undefined undefined-undefined
567891011121314